| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
WC5-2 targets Cytochrome P450 1A1 (CYP1A1), an enzyme belonging to the cytochrome P450 superfamily. CYP1A1 is a monooxygenase that plays a crucial role in the metabolism of various endogenous and exogenous compounds, including polycyclic aromatic hydrocarbons (PAHs) and drugs. As a substrate for CYP1A1, WC5-2 is metabolized by the enzyme, resulting in a fluorescent product that can be quantitatively measured. Its high specificity for CYP1A1 makes it an excellent probe for monitoring the enzyme's activity in biological samples.
|
|---|---|
| ln Vitro |
In vitro activity of WC5-2 is demonstrated by its function as a fluorogenic substrate for CYP1A1. In the presence of active CYP1A1, the compound is converted to its fluorescent metabolite, resorufin. The fluorescence can be quantitatively measured at an emission wavelength of 560-630 nm using an excitation wavelength of 480-530 nm. This activity is directly proportional to the CYP1A1 activity in the sample. Due to its high specificity, WC5-2 shows minimal cross-reactivity with other CYP isoforms, making it a reliable probe for specifically measuring CYP1A1 activity in vitro.
|
| ln Vivo |
In vivo applications for WC5-2 are not standard, as it is primarily a research tool for in vitro assays. However, given its role as a probe for CYP1A1, it could theoretically be used in ex vivo analyses of tissue samples from animal models to assess CYP1A1 activity following experimental interventions. There is no documented use of WC5-2 as a therapeutic agent in vivo, and its application is strictly limited to laboratory research for studying enzyme activity.
|
| Enzyme Assay |
Non-cellular enzyme assays for WC5-2 are performed to measure CYP1A1 activity in various enzyme sources. In these assays, WC5-2 is incubated with a sample containing CYP1A1, such as human or animal tissue preparations or recombinantly expressed enzyme. The reaction is typically carried out in a buffer system at physiological pH and temperature. The enzymatic conversion of WC5-2 to its fluorescent product is then measured using a fluorescence detector. By comparing the fluorescence signal to a standard curve, the specific activity of CYP1A1 in the sample can be quantitatively determined.
|
| Cell Assay |
In vitro cell-based assays using WC5-2 are conducted to measure CYP1A1 activity in cultured cells. Cells are cultured and treated with test compounds or conditions that may modulate CYP1A1 expression or activity. WC5-2 is then added to the cell culture medium, and its conversion to the fluorescent product is measured over time. The fluorescence signal is typically measured using a plate reader. This assay allows for the assessment of CYP1A1 activity in a cellular context, providing insights into the regulation of this enzyme by various stimuli and potential drug candidates.
|
| Animal Protocol |
In vivo animal studies for WC5-2 are not typically performed, as it is a research tool for in vitro enzyme assays. The compound is not intended for use as a therapeutic agent in animal models. However, it could be used in ex vivo analyses, where tissue samples from animal models are collected and used in in vitro assays with WC5-2 to measure CYP1A1 activity. This approach can be used to study the effects of various treatments on CYP1A1 expression and activity in different tissues.
|
| ADME/Pharmacokinetics |
WC5-2 has the molecular formula C15H9NO3 and a molecular weight of 251.24 g/mol. It has a LogP of 1.6. The compound is a solid powder and is soluble in DMSO. It should be stored in a dry, dark place at -20°C for long-term storage or at 0-4°C for short-term storage. Detailed pharmacokinetic parameters such as half-life, volume of distribution, and bioavailability are not applicable as this compound is not used as a systemic therapeutic agent.
|
| Toxicity/Toxicokinetics |
WC5-2 is a research-grade chemical and is not intended for human or therapeutic use. Its safety profile has not been extensively characterized in systemic toxicology studies. As a fluorescent probe, its toxicity is primarily relevant in the context of cell-based assays, where it is used at concentrations that are non-toxic to the cells under study. Standard laboratory safety practices should be followed when handling this compound, as with all research chemicals.
|
| Additional Infomation |
WC5-2 (NUN22847) is a resorufin derivative that serves as a high-specificity fluorescent probe for the quantitative detection of Cytochrome P450 1A1 (CYP1A1) activity. It has the molecular formula C15H9NO3 and CAS number 922722-84-7. This probe is used in in vitro assays to measure CYP1A1 activity in various biological samples, including tissue preparations and cell lysates. WC5-2 is a valuable tool for studying the role of CYP1A1 in drug metabolism and disease. It is not a drug and is strictly a research chemical for laboratory use only.
|
| Molecular Formula |
C15H9NO3
|
|---|---|
| Molecular Weight |
251.2369
|
| Exact Mass |
251.058
|
| Elemental Analysis |
C, 71.71; H, 3.61; N, 5.58; O, 19.10
|
| CAS # |
922722-84-7
|
| PubChem CID |
154706824
|
| Appearance |
Solid powder
|
| LogP |
1.6
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
535
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2=C([H])C(C([H])=C([H])C2=NC2C([H])=C([H])C(=C([H])C1=2)OC([H])([H])C#C[H])=O
|
| InChi Key |
NNMUOZROAZHXPY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H9NO3/c1-2-7-18-11-4-6-13-15(9-11)19-14-8-10(17)3-5-12(14)16-13/h1,3-6,8-9H,7H2
|
| Chemical Name |
7-prop-2-ynoxyphenoxazin-3-one
|
| Synonyms |
WC5-2; WC-5-2; WC 5-2; WC52; WC-52; WC 52; NUN22847; NUN-22847; NUN 22847;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9803 mL | 19.9013 mL | 39.8026 mL | |
| 5 mM | 0.7961 mL | 3.9803 mL | 7.9605 mL | |
| 10 mM | 0.3980 mL | 1.9901 mL | 3.9803 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
